The stock of NewLink Genetics Corp (NASDAQ:NLNK) is a huge mover today! About 413,197 shares traded hands or 12.78% up from the average. NewLink Genetics Corp (NASDAQ:NLNK) has declined 15.16% since March 3, 2016 and is downtrending. It has underperformed by 23.50% the S&P500.
The move comes after 7 months negative chart setup for the $442.66M company. It was reported on Oct, 6 by Barchart.com. We have $12.41 PT which if reached, will make NASDAQ:NLNK worth $57.55M less.
Analysts await NewLink Genetics Corp (NASDAQ:NLNK) to report earnings on November, 1. They expect $-0.62 EPS, down 12.73% or $0.07 from last year’s $-0.55 per share. After $-1.12 actual EPS reported by NewLink Genetics Corp for the previous quarter, Wall Street now forecasts -44.64% EPS growth.
NewLink Genetics Corp (NASDAQ:NLNK) Ratings Coverage
Out of 2 analysts covering NewLink Genetics (NASDAQ:NLNK), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. NewLink Genetics has been the topic of 2 analyst reports since March 23, 2016 according to StockzIntelligence Inc. The company was downgraded on Wednesday, May 11 by SunTrust. The stock of NewLink Genetics Corp (NASDAQ:NLNK) has “Outperform” rating given on Wednesday, March 23 by Robert W. Baird.
According to Zacks Investment Research, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.”
Insitutional Activity: The institutional sentiment decreased to 0.73 in Q2 2016. Its down 0.18, from 0.91 in 2016Q1. The ratio dived, as 34 funds sold all NewLink Genetics Corp shares owned while 32 reduced positions. 11 funds bought stakes while 37 increased positions. They now own 14.35 million shares or 17.92% less from 17.49 million shares in 2016Q1.
Federated Invsts Pa has 128,917 shares for 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 163,131 shares or 0.02% of the stock. Swiss Bancorp has 35,700 shares for 0% of their US portfolio. Proshare Limited Co holds 0% or 24,157 shares in its portfolio. Morgan Stanley accumulated 0% or 25,064 shares. Segall Bryant And Hamill Lc holds 0.08% of its portfolio in NewLink Genetics Corp (NASDAQ:NLNK) for 256,082 shares. Nationwide Fund Advsr holds 0% or 14,160 shares in its portfolio. Secor Cap Advsr Lp has invested 0.03% of its portfolio in NewLink Genetics Corp (NASDAQ:NLNK). Creative Planning accumulated 0% or 3,991 shares. Dimensional Fund Advsr Lp holds 0% of its portfolio in NewLink Genetics Corp (NASDAQ:NLNK) for 45,685 shares. Metropolitan Life Insurance Ny holds 16,225 shares or 0% of its portfolio. Art Advsr Lc has 83,463 shares for 0.05% of their US portfolio. New York State Common Retirement Fund holds 20,000 shares or 0% of its portfolio. Sphinx Trading L P accumulated 5,000 shares or 0.11% of the stock. Blackrock Mngmt Limited Liability Company, a New Jersey-based fund reported 82,103 shares.
More notable recent NewLink Genetics Corp (NASDAQ:NLNK) news were published by: Fool.com which released: “Why NewLink Genetics Corporation Dropped 27.6% in May” on June 10, 2016, also Fool.com with their article: “Why NewLink Genetics Shares Are Crashing 33% Today” published on May 10, 2016, Seekingalpha.com published: “NewLink Genetics Has Many Near-Term Catalysts” on September 27, 2016. More interesting news about NewLink Genetics Corp (NASDAQ:NLNK) were released by: Streetinsider.com and their article: “NewLink Genetics (NLNK) Receives $25M BARDA Contract” published on October 04, 2016 as well as Fool.com‘s news article titled: “Can NewLink Genetics Win the Zika Vaccine Race?” with publication date: February 08, 2016.
NLNK Company Profile
NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a biopharmaceutical firm focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. The Company’s biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. The Company’s additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additional product candidates are also under development for patients with other types of cancer. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod, which target key immune checkpoints. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.